Aspira Women’s Health (NASDAQ:AWH) Upgraded by StockNews.com to “Hold”

StockNews.com upgraded shares of Aspira Women’s Health (NASDAQ:AWH) from a sell rating to a hold rating in a report published on Wednesday.

Aspira Women’s Health Price Performance

Shares of NASDAQ:AWH opened at $1.13 on Wednesday. The business has a 50-day moving average of $1.43 and a two-hundred day moving average of $2.80. The firm has a market capitalization of $14.07 million, a PE ratio of -0.78 and a beta of 1.54. Aspira Women’s Health has a 12 month low of $0.86 and a 12 month high of $6.75.

Aspira Women’s Health (NASDAQ:AWH) last issued its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. The company had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $2.60 million. During the same period in the previous year, the company earned ($0.28) EPS. As a group, research analysts anticipate that Aspira Women’s Health will post -1.3 earnings per share for the current year.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 179,371 shares of the company’s stock after buying an additional 53,997 shares during the period. B. Riley Wealth Advisors Inc. owned 1.73% of Aspira Women’s Health worth $732,000 as of its most recent filing with the Securities and Exchange Commission. 12.19% of the stock is owned by institutional investors and hedge funds.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.